Cargando…
ODP496 Methimazole Induced Agranulocytosis Despite Minimal Intermittent Therapy
INTRODUCTION: Anti-thyroid drugs, such as methimazole (MMI), are standard therapies for the medical management of Graves Disease. Agranulocytosis is a rare but lethal adverse effect of anti-thyroid medications. Here we discuss a case that highlights the importance of monitoring not only in the early...
Autores principales: | Uddin, Ashraf, Gardner, Michael |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9625446/ http://dx.doi.org/10.1210/jendso/bvac150.1596 |
Ejemplares similares
-
SAT-600 Relapse of Agranulocytosis after Recovery of Methimazole-Induced Agranulocytosis
por: Choi, Dughyun, et al.
Publicado: (2019) -
PSAT344 Zeroing In: Methimazole Induced Agranulocytosis in Amiodarone Induced Thyrotoxicosis
por: Gunda, Mouna, et al.
Publicado: (2022) -
FRI505 A Rare Case Of Methimazole Induced Grave Agranulocytosis
por: Barua, Nabonita, et al.
Publicado: (2023) -
Successful Management of Hyperthyroidism With Lithium and Radioiodine in a Patient With Previous Methimazole-Induced Agranulocytosis
por: Fantin, Esther H, et al.
Publicado: (2021) -
SAT-625 Dose-Dependent, Methimazole-Induced Agranulocytosis in a Pregnant Hispanic Woman with Grave's Disease
por: Bello, Fatimah, et al.
Publicado: (2019)